CorMedix Inc. (CRMD) Financial Statements (2024 and earlier)

Company Profile

Business Address 300 CONNELL DRIVE
BERKELEY HEIGHTS, NJ 07922
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments58,79265,46646,35028,33417,62411,984
Cash and cash equivalents43,14853,31741,90516,35017,62410,380
Short-term investments15,64412,1494,44411,984 1,604
Restricted cash and investments124132191   
Receivables     1164
Inventory, net of allowances, customer advances and progress billings  3144338429594
Inventory  3144338429594
Prepaid expense11526235887
Deposits current assets   20   
Other undisclosed current assets6248161,416641594539
Total current assets:59,55166,46948,18229,34918,66513,268
Noncurrent Assets
Operating lease, right-of-use asset7759001,015 
Property, plant and equipment1,6101,475111127161186
Restricted cash and investments102102    
Total noncurrent assets:2,4872,4771,126127161186
TOTAL ASSETS:62,03868,94649,30829,47618,82613,454
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,1765,2244,0525,8257,7556,172
Accounts payable2,2022,2101,1281,0242,5891,808
Accrued liabilities3,9743,0142,9244,8005,1664,364
Deferred revenue    2
Other undisclosed current liabilities135121109 1188
Total current liabilities:6,3115,3454,1625,8277,7666,261
Noncurrent Liabilities
Long-term debt and lease obligation  80292436,125 
Long-term debt, excluding current maturities     6,125 
Liabilities, other than long-term debt668     
Operating lease, liability6688029243
Other undisclosed noncurrent liabilities  (802)(924)   
Total noncurrent liabilities:66880292436,125 
Total liabilities:6,9796,1485,0855,83013,8926,261
Equity
Equity, attributable to parent, including:55,06062,79844,22323,6464,9347,193
Preferred stock000000
Common stock4338342610971
Common stock, value, subscriptions    15,200  
Additional paid in capital330,295308,332261,5366183,717159,198
Accumulated other comprehensive income8387102979798
Accumulated deficit(275,361)(245,659)(217,449)(195,421)(178,988)(152,175)
Other undisclosed equity, attributable to parent    203,738  
Total equity:55,06062,79844,22323,6464,9347,193
TOTAL LIABILITIES AND EQUITY:62,03868,94649,30829,47618,82613,454

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues65191239283430329
Cost of revenue(4)(149)(205)(373)(397)(115)
Gross profit:624234(90)33214
Operating expenses(30,686)(29,480)(27,255)(20,918)(26,897)(33,138)
Other operating expense, net
(Other Expenses)
    (2)  
Other undisclosed operating income    2  
Operating loss:(30,624)(29,438)(27,221)(21,008)(26,864)(32,924)
Nonoperating income (expense)337(23)2430235110
Investment income, nonoperating    323 124
Other nonoperating income (expense)337(23)24 35 
Interest and debt expense(27)(16)(33)(787)(2)(6)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes   33(0)2(190)
Loss from continuing operations before equity method investments, income taxes:(30,314)(29,476)(27,197)(21,494)(26,830)(33,010)
Other undisclosed income from continuing operations before income taxes2716 0  
Loss from continuing operations before income taxes:(30,287)(29,460)(27,197)(21,494)(26,830)(33,010)
Income tax benefit 5861,2505,1695,061  
Loss from continuing operations:(29,702)(28,210)(22,028)(16,433)(26,830)(33,010)
Loss before gain (loss) on sale of properties:(28,210)(22,028)(16,433)(26,830)(33,010)
Net loss:(29,702)(28,210)(22,028)(16,433)(26,830)(33,010)
Net loss attributable to noncontrolling interest  (28,200)    
Other undisclosed net income attributable to parent 28,200   0
Net loss attributable to parent:(29,702)(28,210)(22,028)(16,433)(26,830)(33,010)
Other undisclosed net loss available to common stockholders, basic    (27,103)  
Net loss available to common stockholders, diluted:(29,702)(28,210)(22,028)(43,536)(26,830)(33,010)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(29,702)(28,210)(22,028)(16,433)(26,830)(33,010)
Other comprehensive income (loss)(4)(15)51(2) 
Comprehensive loss:(29,706)(28,225)(22,023)(16,432)(26,832)(33,010)
Comprehensive loss, net of tax, attributable to noncontrolling interest  (28,200)    
Other undisclosed comprehensive income, net of tax, attributable to parent 28,200   17
Comprehensive loss, net of tax, attributable to parent:(29,706)(28,225)(22,023)(16,432)(26,832)(32,993)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: